Berenson Cancer Center in the news

Interviews & Videos

HealthTree Foundation

Has built many patient programs and over 8 integrated software platforms to help blood cancer patients learn more about their disease and better navigate their disease. Interviewed Dr. Berenson on phase 1 data and others. Outcomes of Triple Class Refractory Multiple Myeloma Patients | James Berenson, MD | ASH 2023

Assessing Lenalidomide with Patients Progressing on JAK Inhibitors

James Berenson, MD | ASH 2023

Medical Writing Bias in Myeloma Clinical Research

Interview with James Berenson, MD, from Institute for Myeloma and Bone Cancer Research at ASH 2023.

MedPage Today: Senior Oncology Editor, Charles Bankhead videotaped an interview with Dr. Berenson on the JAK inhibitor data being presented

Circulation: 1,838,691. LinkedIn: 4,929 followers. X Twitter: 6,101 Following. 77.4K Followers

Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease

Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease.Following is a transcript of his remarks

news image

Drugs Used for Myeloma are Helping Fight COVID-19

Several anti-inflammatory drugs used to treat multiple myeloma are showing promising results treating Covid-19.

pill lady

Can Diet And Supplements Prevent Smoldering Myeloma From Progressing

Is there a proven diet that can keep smoldering myeloma from progressing? What about fasting and taking supplements? What do the experts recommend?

man arms crossed

Does Smoldering Myeloma Treatment Need To Be Aggressive?

Smoldering myeloma happens when changes in the blood are caught early in a blood test and is a precursor to multiple myeloma. What is it like living with smoldering myeloma and how aggressively should you be monitored and treated?

KTTV June 10, 2021

KNBC June 14, 2021

KCAL June 14, 2021